Invitro activity of gemifloxacin against some clinical bacterial isolates of urinary tract infections
Main Article Content
Abstract
Background: Gemifloxacin is a third generation fluoroquinolone with broad spectrum antimicrobial and enhanced activity against both aerobic and anaerobic Gram positive bacteria. It is recommended for the treatment of respiratory tract infections.
Objectives: This study evaluated and compared the antibacterial activity of gemifloxacin with ciprofloxacin, ofloxacin and norfloxacin using minimum inhibition concentration assays against Staphylococcus aureus, Escherichia coli, Alcaligenes faecalis, Pseudomonas aeruginosa, Serratia marcescens, Enterobacter aerogenes, Proteus vulgaris and Klebseilla pneumoniae obtained from urine samples of patients.
Methods: The minimum inhibition concentration (MIC) evaluations were employed for the comparative studies and zones of inhibition assay were further used to determine the antibacterial activity of gemifloxacin. For the MIC evaluations, final nutrient agar concentrations of 5, 7.5, 10, 15, 20, 25 and 30µg/ml of gemifloxacin, ciprofloxacin, ofloxacin, and norfloxacin were used. For the zones of inhibition assay, 0.2ml of the MICs (7.5, 10, 15, 25 and 30 µg/ml) of gemifloxacin against particular bacterium was used.
Results: The MICs of gemifloxacin were 7.5µg/ml for Proteus vulgaris, 10µg/ml for Staphylococcus aureus and Enterobacter aerogenes, 15µg/ml for E. coli, 20µg/ml for Pseudomonas aeruginosa, 25µg/ml for Klebsiella pneumonia and 30µg/ml for Alcaligenes faecalis and Serratia marcescens. The clinical isolates were most sensitive to ofloxacin with MICs of 7.5µg/ml for Proteus vulgaris and 10µg/ml for the other isolates. The isolates were least susceptible to norfloxacin with MICs of 10µg/ml for Proteus vulgaris and 30µg/ml for the other isolates.
The results show that the clinical isolates were most sensitive to ofloxacin followed by gemifloxacin, ciprofloxacin and norfloxacin respectively.
Conclusion: Although gemifloxacin is not currently strongly recommended for urinary tract infections, this study has shown that it possesses antibacterial activity against the clinical isolates obtained from urine samples of patients with urinary tract infections and could have a place in the treatment of urinary tract infections caused by the organisms.
Key words: Gemifloxacin, urinary tract infections, invitro activity.
Downloads
Article Details
How to Cite
Share
References
Catherine M. Oliphant, Gary M and Green, M.D. Quinolones: A Comprehensive Review. American Family Physician, 2002; 65(3):455 -465.
Owens, RC and Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am, 2000; 84:14471469.
Donaldson, PM,Pallett, AP and Carroll, MP. Ciprofloxacin in general practice British Med Journal (Clinical Research Ed.), 1994; 308: 1437-1443
Monk JP and Campoli-Richards DM.. Ofloxacin: A review of its antibacterial activity ,pharmacokinetic properties and therapeutic uses. .Drugs, 1987; 33(4): 346 - 3491
Padeiskaia, EN. Norfloxacin: more than 20 years of clinical use, the results and place among fluoroquinolones in modern chemotherapy for
infections. Antibiot Khimioter, 2003; 48 (9): 2836.
Jones RN and Pfaller, MA. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clinical Infectious Disease, 2000; 31:16 23.
McCloskey, L, Maore, T, Niconovich, N., Donald, B., Broskey, J., Jaklelasszek, Rettenhouse, S., and Coleman, K. In Vitro activity of gemifloxacin
againsta broad range of recent clinical isolates from the USA. J. Antimicrobial Chemother, 2000; 45: 13 21.
Karageorgopoulos,DE, Giannopoulou, KP, Grammatikos, AP, Dimopoulos, G, and Falagas, ME. Fluoroquinolones compared with betalactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ, 2008; 178 (7): 845 854.
Cheesbrough, M.. District Laboratory practice in Tropical Countries, Low price edition, Gambridge Univ. press, Gambridge, 2004; p. 63 70.
George ME and Robert CM. Antimicrobial combinations In: Antibiotics in medicine, 4th Ed. Victor, L. editor, Williams and Wilkens,1996; p.
Perez C, Paul M and Bazerque P. Antibiotic assay by agar-well diffusion method. Acta Biol Med Exp, 1990; 15: 113 115.
Calva, JJ., Sifuentes-Osornio, J. and Ceron, C. Antimicrobial resistance in fecal flora: longitudinal community-based surveillance of children from urban Mexico. Antimicrob Agents Chemother, 1996; 40(1): 699-702.
Lau, SM, Peng MY and Chang, FY. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and nonbacteremic communityacquired urinary tract infection. Microbiol Immunol Infect, 2004; 37(3) :185-189.
Lau, SM, Peng MY and Chang, FY. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and nonbacteremic communityacquired urinary tract infection. Microbiol Immunol Infect, 2004; 37(3) :185-189.